Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Cash (2016 - 2025)

Cytokinetics (CYTK) has disclosed Change in Cash for 16 consecutive years, with $96.5 million as the latest value for Q4 2025.

  • Quarterly Change in Cash changed N/A to $96.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $30.4 million for FY2025, 267.34% up from the prior year.
  • Change in Cash for Q4 2025 was $96.5 million at Cytokinetics, up from -$21.2 million in the prior quarter.
  • The five-year high for Change in Cash was $96.5 million in Q4 2025, with the low at -$143.3 million in Q3 2024.
  • Average Change in Cash over 5 years is $2.3 million, with a median of $7.0 million recorded in 2024.
  • The sharpest move saw Change in Cash soared 1207.47% in 2023, then tumbled 561.32% in 2024.
  • Over 5 years, Change in Cash stood at $22.1 million in 2021, then plummeted by 276.69% to -$39.1 million in 2022, then skyrocketed by 134.14% to $13.3 million in 2023, then plummeted by 1174.51% to -$143.3 million in 2024, then skyrocketed by 167.39% to $96.5 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $96.5 million, -$21.2 million, and -$143.3 million for Q4 2025, Q1 2025, and Q3 2024 respectively.